Artículos relacionados a Sensitising cervix against cancer: Addition of gemcitabine...
Sensitising cervix against cancer: Addition of gemcitabine to standard therapy in locally advanced cervical cancer: A randomized comparative study - Tapa blanda
Reseña del editor
The concurrent Chemoradiotherapy for cervical cancer treatment is well accepted since 1999. This study was aimed to observe if any improved outcome could be obtained capitalizing on the synergistic activity of Gemcitabine, Cisplatin, XRT. Stage IIB-IIIB were randomized to control group and study group. Control group received Cisplatin 40 mg/m2 weekly with concurrent XRT, followed by brachytherapy and study group received Gemcitabine 125 mg/m2 weekly top of the same control group treatment. The primary end-point was pathological response and toxicities along with patient compliance to treatment, late reactions, DFS & OS in a scenario like our local community. The complete response was slightly better in study arm. Toxicities were significantly high in the study group compared to control group. The distant failure prevailed in control arm. On a median follow up of little less than two years, the DFS in study arm was slightly better than control arm. If the toxicity can be managed adequately in the combination chemo radiation group, it may produce an improvement in response. Survival benefit can also be obtained by introducing gemcitabine to cisplatin as radio sensitizer.
Biografía del autor
Dr. Sanjoy Roy has been trained in Radiation Oncology from C.N.C.I and is attached with the department since 2006. His area of interest is Cervical cancer and Breast conservation. Currently he is involved in Conformal Therapy delivery technique in Cervical Cancer and also delivers training & guidance to DNB PG trainees.
"Sobre este título" puede pertenecer a otra edición de este libro.
- EditorialLAP LAMBERT Academic Publishing
- Año de publicación2012
- ISBN 10 3659146692
- ISBN 13 9783659146695
- EncuadernaciónTapa blanda
- Número de páginas76
EUR 113,35
Gastos de envío:
EUR 29,91
De Reino Unido a Estados Unidos de America
Comprar nuevo
Ver este artículo
EUR 47,14
Gastos de envío:
EUR 3,58
A Estados Unidos de America
Los mejores resultados en AbeBooks
Imagen de archivo
Sensitising cervix against cancer: Addition of gemcitabine to standard therapy in locally advanced cervical cancer: A randomized comparative study
Publicado por
LAP LAMBERT Academic Publishing, 2012
ISBN 10: 3659146692
ISBN 13: 9783659146695
Nuevo
Tapa blanda
Librería: Lucky's Textbooks, Dallas, TX, Estados Unidos de America
Calificación del vendedor: 5 de 5 estrellas
Condición: New. Nº de ref. del artículo: ABLIING23Mar3113020265995
Cantidad disponible: Más de 20 disponibles
Imagen de archivo
Sensitising cervix against cancer Addition of gemcitabine to standard therapy in locally advanced cervical cancer A randomized comparative study
Publicado por
LAP LAMBERT Academic Publishing, 2012
ISBN 10: 3659146692
ISBN 13: 9783659146695
Nuevo
PAP
Librería: PBShop.store UK, Fairford, GLOS, Reino Unido
Calificación del vendedor: 5 de 5 estrellas
PAP. Condición: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Nº de ref. del artículo: IQ-9783659146695
Gastos de envío:
EUR 3,94
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío
Cantidad disponible: 15 disponibles
Imagen de archivo
Sensitising cervix against cancer
Publicado por
LAP Lambert Academic Publishing, 2012
ISBN 10: 3659146692
ISBN 13: 9783659146695
Nuevo
Tapa blanda
Librería: Ria Christie Collections, Uxbridge, Reino Unido
Calificación del vendedor: 5 de 5 estrellas
Condición: New. PRINT ON DEMAND Book; New; Fast Shipping from the UK. No. book. Nº de ref. del artículo: ria9783659146695_lsuk
Gastos de envío:
EUR 11,94
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío
Cantidad disponible: Más de 20 disponibles
Imagen de archivo
Sensitising cervix against cancer Addition of gemcitabine to standard therapy in locally advanced cervical cancer A randomized comparative study
Publicado por
LAP LAMBERT Academic Publishing, 2012
ISBN 10: 3659146692
ISBN 13: 9783659146695
Nuevo
PAP
Librería: PBShop.store US, Wood Dale, IL, Estados Unidos de America
Calificación del vendedor: 5 de 5 estrellas
PAP. Condición: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Nº de ref. del artículo: L0-9783659146695
Cantidad disponible: Más de 20 disponibles
Imagen de archivo
Sensitising cervix against cancer
Publicado por
LAP Lambert Academic Publishing 2012-06, 2012
ISBN 10: 3659146692
ISBN 13: 9783659146695
Nuevo
PF
Librería: Chiron Media, Wallingford, Reino Unido
Calificación del vendedor: 5 de 5 estrellas
PF. Condición: New. Nº de ref. del artículo: 6666-IUK-9783659146695
Gastos de envío:
EUR 18,53
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío
Cantidad disponible: 10 disponibles
Imagen del vendedor
Sensitising cervix against cancer
Publicado por
LAP Lambert Academic Publishing, 2012
ISBN 10: 3659146692
ISBN 13: 9783659146695
Nuevo
Taschenbuch
Librería: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Alemania
Calificación del vendedor: 5 de 5 estrellas
Taschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The concurrent Chemoradiotherapy for cervical cancer treatment is well accepted since 1999. This study was aimed to observe if any improved outcome could be obtained capitalizing on the synergistic activity of Gemcitabine, Cisplatin, XRT. Stage IIB-IIIB were randomized to control group and study group. Control group received Cisplatin 40 mg/m2 weekly with concurrent XRT, followed by brachytherapy and study group received Gemcitabine 125 mg/m2 weekly top of the same control group treatment. The primary end-point was pathological response and toxicities along with patient compliance to treatment, late reactions, DFS & OS in a scenario like our local community. The complete response was slightly better in study arm. Toxicities were significantly high in the study group compared to control group. The distant failure prevailed in control arm. On a median follow up of little less than two years, the DFS in study arm was slightly better than control arm. If the toxicity can be managed adequately in the combination chemo radiation group, it may produce an improvement in response. Survival benefit can also be obtained by introducing gemcitabine to cisplatin as radio sensitizer. 76 pp. Englisch. Nº de ref. del artículo: 9783659146695
Gastos de envío:
EUR 23,00
De Alemania a Estados Unidos de America
Destinos, gastos y plazos de envío
Cantidad disponible: 2 disponibles
Imagen del vendedor
Sensitising cervix against cancer : Addition of gemcitabine to standard therapy in locally advanced cervical cancer: A randomized comparative study
Publicado por
LAP Lambert Academic Publishing, 2012
ISBN 10: 3659146692
ISBN 13: 9783659146695
Nuevo
Taschenbuch
Librería: AHA-BUCH GmbH, Einbeck, Alemania
Calificación del vendedor: 5 de 5 estrellas
Taschenbuch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - The concurrent Chemoradiotherapy for cervical cancer treatment is well accepted since 1999. This study was aimed to observe if any improved outcome could be obtained capitalizing on the synergistic activity of Gemcitabine, Cisplatin, XRT. Stage IIB-IIIB were randomized to control group and study group. Control group received Cisplatin 40 mg/m2 weekly with concurrent XRT, followed by brachytherapy and study group received Gemcitabine 125 mg/m2 weekly top of the same control group treatment. The primary end-point was pathological response and toxicities along with patient compliance to treatment, late reactions, DFS & OS in a scenario like our local community. The complete response was slightly better in study arm. Toxicities were significantly high in the study group compared to control group. The distant failure prevailed in control arm. On a median follow up of little less than two years, the DFS in study arm was slightly better than control arm. If the toxicity can be managed adequately in the combination chemo radiation group, it may produce an improvement in response. Survival benefit can also be obtained by introducing gemcitabine to cisplatin as radio sensitizer. Nº de ref. del artículo: 9783659146695
Gastos de envío:
EUR 32,99
De Alemania a Estados Unidos de America
Destinos, gastos y plazos de envío
Cantidad disponible: 2 disponibles
Imagen del vendedor
Sensitising cervix against cancer
Publicado por
LAP LAMBERT Academic Publishing, 2012
ISBN 10: 3659146692
ISBN 13: 9783659146695
Nuevo
Kartoniert / Broschiert
Librería: moluna, Greven, Alemania
Calificación del vendedor: 5 de 5 estrellas
Kartoniert / Broschiert. Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Roy SanjoyDr. Sanjoy Roy has been trained in Radiation Oncology from C.N.C.I and is attached with the department since 2006. His area of interest is Cervical cancer and Breast conservation. Currently he is involved in Conformal Thera. Nº de ref. del artículo: 5134864
Gastos de envío:
EUR 48,99
De Alemania a Estados Unidos de America
Destinos, gastos y plazos de envío
Cantidad disponible: Más de 20 disponibles
Imagen de archivo
Sensitising cervix against cancer: Addition of gemcitabine to standard therapy in locally advanced cervical cancer: A randomized comparative study
Publicado por
LAP LAMBERT Academic Publishing, 2012
ISBN 10: 3659146692
ISBN 13: 9783659146695
Antiguo o usado
Paperback
Librería: Mispah books, Redhill, SURRE, Reino Unido
Calificación del vendedor: 4 de 5 estrellas
Paperback. Condición: Like New. Like New. book. Nº de ref. del artículo: ERICA79636591466926
Gastos de envío:
EUR 29,91
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío
Cantidad disponible: 1 disponibles